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Abstract
Chromosomal instability (CIN) is one of the common features in prostate cancer, especially in advanced stages. Recently,
the involvement of p53 in CIN through the regulation of centrosome amplification has been proposed in certain tumor types.
In this study, we investigated the relationship between p53 and centrosome amplification in prostate cancer cells. Increased
centrosome number and size were observed in DU145 and PC3 containing nonfunctional p53 compared to LNCap which
expressed wild-type p53. Transfection of p53 into PC3 cells resulted in a decreased cell growth rate, G2/M arrest and
decreased centrosome abnormalities. We provide the first evidence on a correlation between loss of p53 function and
centrosome amplification in prostate cancer cells. Our results indicate that p53 may play a role in the regulation of
centrosome amplification and loss of p53 may be one of the mechanisms involving CIN in prostate cancer cells. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
The fact that aneuploidy is found in most of the
human malignancies indicates that chromosome in-
stability (CIN) may play important roles in the tu-
morigenesis process. Recent studies suggest that cen-
trosome defects may be one of the major causes of
CIN and contribute signi¢cantly to aneuploidy and
tumor development and progression in certain tumor
types including prostate cancer [1^4]. Centrosomes
consist of a pair of centrioles surrounded by a pro-
tein matrix. Each cell contains one (before a cell
division) or two (during mitosis) centrosomes. Dur-
ing mitosis, the two centrosomes form two spindle
poles that direct the assembly of the microtubules,
which are essential for balanced chromosome segre-
gation [5]. Association between centrosome abnor-
mality and CIN has been reported in many types
of cancers including breast, prostate, brain, lung, co-
lon, pancreatic and liver. Changes in centrosome
numbers (from one or two copies to more than three
copies per cell), shape (from uniformed spots to ir-
regular shape and structure) and size (enlarged) have
been found in various types of tumor tissues which
show abnormal mitosis [1,6^8]. In addition, mouse
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embryonal ¢broblasts (MEF) with defective centro-
somes display chromosome missegregation and aneu-
ploidy [9]. Therefore, it has been suggested that cen-
trosome abnormalities may induce spindle defects
that lead to the imbalanced segregation of chromo-
somes, which can contribute to tumorigenesis by ei-
ther losing tumor suppression or gaining tumor on-
cogenesis [1,5].
The mechanisms leading to centrosome abnormal-
ities and the factors that may regulate centrosome
function are still largely unknown. Recently, some
centrosome associated factors have been implicated
such as cdk-2 and cyclin E [10,11], tumor-associated
kinase STK15/BTAK [12], MDM2 [4], and most im-
portantly, the involvement of the p53 tumor suppres-
sor protein [13,14], in the regulation of centrosomes.
Centrosome hyperampli¢cation has been observed in
p533/3 MEF cells which also show abnormalities in
controlling both initiation of centrosome duplication
and suppression of reduplication [11,13,14]. Expres-
sion of HPV E6/E7 oncoproteins, which inactivate
both pRB and p53, resulted not only in an abnormal
centrosome copy numbers but also increased size in
human keratinocytes [15]. Over expression of
MDM2, which inactivates p53, also leads to the am-
pli¢cation of centrosomes in mouse 3T3 cells [4]. In
addition, expression of a gain-of-function mutant
p53 protein in human mammary epithelial cells has
been shown to result in ampli¢cation of centrosomes
which is accompanied by an increased genomic insta-
bility [16]. Furthermore, p53 has been demonstrated
to localize in the mitotic spindles and centrosomes
during mitosis further implicating its involvement
in the regulation of spindle checkpoint [17]. These
observations strongly suggest that p53 may play an
important role in the regulation of the function of
centrosomes.
Prostate cancer is one of the most common can-
cers in men. Although a majority of patients bene¢t
from hormone depletion therapy, a substantial
number of patients still die every year. Understand-
ing the mechanisms involved in prostate tumorigen-
esis may provide information on designing new
treatment strategies. One of the common features
of prostate cancer is the mutation of the p53
gene, which occurs in over 50% prostate cancer
cases [18]. Abnormal p53 expression is also associ-
ated with increased stage and grade of this cancer
[19,20]. In addition, chromosome instability and
centrosome abnormalities are common events in
prostate cancer and abnormal mitosis and chromo-
somal abnormalities are frequently found in pros-
tate cancer tissues and established cell lines [1,3,5].
In order to investigate the involvement of p53 in
centrosome ampli¢cation in prostate cancer cells,
we analyzed centrosomes in three prostate cancer
cell lines with di¡erent p53 status, LNCap (with
wide type p53, [21]), DU145 (carrying mutations
at codon 274 and 223, [22]) and PC3 (with deleted
p53 gene, [22,23]). We found a signi¢cant increase
in centrosome numbers in cell lines with nonfunc-
tional p53. In addition, we transfected a wild-type
p53 gene into the p53 negative PC3 cell line and
studied its e¡ect on centrosome ampli¢cation. Our
results suggest that inactivation of p53 is associated
with centrosome ampli¢cation and introduction of
wild-type p53 into PC3 cells leads to a G2/M phase
arrest and a decrease in centrosome abnormalities
in these cells. Our results indicate that p53 may
play an important part in maintaining the normal
function of centrosome and G2/M checkpoint con-
trol.
2. Materials and methods
2.1. Cell lines and cell culture
Human prostate cancer cell lines LNCap, PC3 and
DU145 were obtained from American Tissue Culture
Collection (ATCC, Manassas, VA) and maintained
in RPMI1640 medium supplemented with 10% fetal
calf serum, and penicillin (50 units/ml) and strepto-
mycin (50 Wg/ml) 37‡C.
2.2. Immuno£uorescence staining of centrosomes
Cells were grown on 4-mm chamber slides and
washed three times with phosphate-bu¡ered saline
(PBS). Cells were incubated with permeabilization
bu¡er (80 mM PIPES (pH 6.8), 5 mM EGTA,
1 mM MgCl2 and 0.5% Triton X-100) for 60 s at
room temperature. The slides were washed with
PBS three times and then ¢xed in cold methanol
(320‡C) for 5 min and washed three times in PBS.
Then they were incubated in blocking solution (1U
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PBS, 0.5% Triton X-100 and 2% bovine serum albu-
min (BSA) for 10 min at room temperature. Slides
were washed again in PBS and incubated with pri-
mary monoclonal antibody against Q-tubulin (1:500,
Sigma Chemical Co., St. Louis, MO) for 1 h at 37‡C.
After washing three times with PBS, the slides were
incubated with FITC-labeled goat anti-mouse anti-
body (1:50, DAKO, Glostrup, Denmark) for 1 h at
37‡C followed by three washes in PBS. Cells were
then counterstained with propidium iodide (1 Wg/
ml, PI), immersed in an antifade solution and over-
laid with a coverslip. Images were analyzed using a
Laser Scanning Confocal Imaging System (MRC
1024, Bio-Rad Laboratories, Richmond, CA). Each
experiment was repeated three times and at least 500
cells were evaluated in each experiment. The centro-
somes were considered to be uniform if the di¡erence
in the diameter of centrosomes in each cell line was
less than twofold. Centrosomes in the metaphase
cells were recognized as a small single dot close to
the nuclear membrane while in mitotic cells, a pair of
dots was detected, one at each pole of the spindle [8].
Centrosomes that were di¡erent from those described
above or appeared more than three copies per cell
were considered to be abnormal.
2.3. Generation of stable p53 transfectants
PC3 cells were transfected with pC53-SN3 vector
carrying a wild-type p53 construct and its corre-
sponding control vector (pCMV) [24] using Fugene
(Roche, Indianapolis, IN) according to manufactur-
er’s protocols. Stable transfectants were selected in
G418 (500 Wg/ml) and individual pC53-SN3 transfec-
tant clones were isolated after 14 days of selection.
The corresponding vector control cells (PC3-pCMV)
were generated as a pool of over 50 individual clones
resistant to G418. Three p53 expressing clones with
di¡erent p53 levels, named PC3-p53C1^3, were se-
lected for further analysis.
2.4. Western blotting analysis
Cellular protein was isolated by resuspending cell
pellets in lysis bu¡er (50 mM Tris^HCl (pH 8.0), 150
mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS) includ-
ing protease inhibitors (1 Wg/ml aprotinin, 1 Wg/ml
leupeptin, 1 mM PMSF), and protein concentrations
were measured using the protein assay kit (Bio-Rad).
Fifty Wg protein was separated by electrophoresis on
a 12.5% sodium dodecyl sulfate^polyacrylamide gel
(SDS^PAGE) and blotted onto the nitrocellulose
membrane (Amersham, Buckinghamshire, UK).
After blocking with 5% (w/v) nonfat milk containing
2% (w/v) BSA in TBS for 1 h, the blots were incu-
bated with primary antibody against p53 (1:200,
monoclonal, Oncogene Science, Cambridge, MA)
for 1 h at room temperature, followed by incubation
with horseradish peroxidase-conjugated secondary
antibody (1:1000, Amersham) for another 1 h. The
immunoreactive signals were detected by ECL Plus
Western blot detection reagents (Amersham) accord-
ing to manufacturer’s instructions.
2.5. Cell cycle analysis
Cells (5U105) were trypsinized and washed once in
PBS. They were then ¢xed in cold 70% ethanol and
stored at 4‡C. Before testing, the ethanol was re-
moved and the cells were resuspended in PBS. The
¢xed cells were then washed with PBS and treated
with RNase (1 Wg/ml) and stained with propidium
iodide (50 Wg/ml) for 30 min at 37‡C. Cell cycle anal-
ysis was performed on an EPICS pro¢le analyzer and
analyzed using the ModFit LT2.0 software (Coulter
Electronics, Hialeah, FL).
2.6. 5-Bromo-2P-deoxyuridine (BrdU) incorporation
Cells grown on 4-mm Chamber slides (ICN, Bio-
medicals, Aurora, OH) were treated with BrdU (10
WM) for 2 h and then washed once with PBS. The
cells were then ¢xed in cold methanol/acetone (1:1)
for 5 min at room temperature and washed in PBS.
The cells were incubated with monoclonal antibody
against BrdU (1:10, Roche) for 1 h at 37‡C and de-
tailed procedures were described in the protocols
provided in Vectastain ABC kit (Vector Laboratories
Burlingame, CA). Each experiment was repeated
three times and at least 1000 cells were evaluated in
each experiment. The percentage of BrdU-positive
cells in PC3 cells transfected with control vector
(pCMV) or p53 expression vector (PC53-SN) were
compared to the parental PC3 cells. The error bars
in the Figures represent the standard deviation (S.D.)
from three independent experiments.
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3. Results
3.1. Centrosome status in LNCap, DU145 and
PC3 prostate cancer cell lines
The expression of p53 protein was ¢rst studied on
three prostate cancer cell lines, LNCap, DU145 and
PC3 (Fig. 1A). LNCap cells have been reported to
contain wild-type p53 [21] and in this study, a p53-
speci¢c band was detected. DU145 cells have been
shown to harbor a mutated p53 gene resulting in the
expression of a mutated p53 protein [22]. As the anti-
body used in the present study recognized both wild-
type and mutated p53 proteins, a p53 protein band
was also observed in DU145 cell line. In PC3 cell line
Fig. 2. Representative immunostaining of centrosomes in
LNCap (A), DU145 (B) and PC3 cell lines (C). The cells were
immunostained for centrosomes as described in the legend to
Fig. 1B. The arrowheads indicate centrosomes. (A) An LNCap
cell containing a single centrosome; (B) A DU145 cell contain-
ing three copies of centrosomes with di¡erent sizes; (C) A PC3
cell containing two copies of centrosomes with di¡erent sizes.
The images were captured on a Laser Scanning Confocol Imag-
ing System (MRC, 1024, Bio-Rad) under 400U magni¢cation.
Fig. 1. Expression of p53 (A) and the presence of centrosomes (B) in prostate cancer cell lines LNCap, DU145 and PC3. (A) Fifty Wg
of protein was analyzed using Western blotting analysis. The expression of actin was examined as an internal loading control.
(B) Cells were stained with primary monoclonal anti-Q-tubulin antibody (1:500, Sigma Chemical Co., St. Louis, MO) and then FITC-
labeled goat anti-mouse antibody (1:50, DAKO, Glostrup, Denmark). The cells were then counterstained with propidium iodide
(1 Wg/ml, PI) for visualization of nuclei. At least 500 cells were evaluated in each experiment and the error bars indicate the S.E.M.
from three independent experiments.
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Fig. 3. E¡ect of p53 expression on PC3 cells. (A) p53 protein expression in the stable PC3 transfectants PC3-p53C1-3, vector control
(PC3-pCMV), parental PC3 and LNCap cells. Fifty Wg protein was analyzed using Western blotting analysis. (B) Percentage of BrdU
incorporation in vector control (PC3-pCMV) and p53 transfectants (PC3-p53C1^3) compared to the parental PC3 cells. The error
bars indicate the S.E.M. from three independent experiments. (C) Cell cycle changes after expression of p53 in PC3 cells. 5U105 cells
were studied on an EPICS pro¢le analyzer and analyzed using the ModFit LT2.0 software (Coulter).
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with p53 gene deleted [22,23], no p53 protein expres-
sion was observed (Fig. 1A).
These three cell lines were then examined for cen-
trosomes by immunostaining using antibody against
Q-tubulin. Q-Tubulin is one of the major components
of the centrosomes and immunostaining of Q-tubulin
is able to detect centrosomes through out the cell
cycle [11]. As shown in Fig. 1B, there was a signi¢-
cant di¡erence in centrosome copy numbers among
these three cell lines. A majority of LNCap cells
(65.8%) contained one copy of centrosome, which
appeared localized closely to the nuclear membrane
(Fig. 2A). Two copies of centrosomes were observed
in 28% of the LNCap and a small percentage (6.2%)
of LNCap cells contained three or more copies of
centrosomes. The morphology of the centrosomes
in LNCap cells appeared to be uniformly rounded
spots with similar size. In contrast, there was a sig-
ni¢cant di¡erence in centrosome number and mor-
phology in DU145 and PC3 cells (Fig. 2B,C). A
small percentage of cells (6.4% and 10.8%, respec-
tively) contained one copy of centrosome, while a
high percentage (83.2% and 41.2%, respectively) of
cells contained more than three copies (Fig. 1B, b
and c). In addition, the structure of centrosomes in
these cells was irregular either within a cell or be-
tween individual cells. Even in the cells containing
less than two copies of centrosomes, their sizes
were not uniform (Fig. 2B,C).
3.2. E¡ect of p53 on centrosome ampli¢cation in
PC3 cells
A plasmid containing wild-type p53 gene (pC53-
SN3) and the corresponding control vector
(pCMV) were transfected into PC3 cells and the sta-
ble transfectants were selected in G418 (500 Wg/ml).
Three p53 expressing clones and a vector control
were studied in detail. While the vector control
PC3-pCMV and parental PC3 cells showed no de-
tectable levels of p53 protein, the three G418 selected
PC3-p53 clones, PC3-p53C1^3, showed di¡erential
p53 expression levels, with PC3-p53C2 containing
the highest levels of p53 protein (Fig. 3A). Upon
transfection of p53, the morphology of PC3 cells be-
came irregular, from mainly uniformed spindle like
cells to a cell population containing signi¢cant per-
centage of enlarged and multinucleated cells. In ad-
dition, the p53 transfectants showed decreased
growth rates (data not shown). BrdU incorporation
assays and £ow cytometric analysis were then used to
evaluate the growth property of these cells. BrdU
incorporation assay showed that during a 2-h incu-
bation period, there was a decrease (15^20%) in the
percentage of BrdU-positive cells in PC3-p53 cells
compared to the vector control (Fig. 3B). These re-
sults agreed with cell cycle analysis data which
showed that there was a decrease in the percentage
of S-phase cells after transfection of p53, although
the percentage of S-phase cells was found to be high-
er than that determined by BrdU incorporation (Fig.
3C). There was also an increase in the percentage of
G2/M cells (11^15%) in the PC3-p53 cells compared
to the vector control cell line. This indicates that
transfection of p53 into PC3 cells might result in
growth inhibition through the induction of G2/M
delay.
PC3-p53 and vector control cells were then exam-
ined for centrosomes. As expected, centrosomes in
PC3-pCMV cells showed a pattern similar to that
Fig. 4. Reduction of centrosome ampli¢cation after transfection
of p53 in PC3 cells. Cells were stained with anti-Q-tubulin anti-
body as described in the legend to Fig. 1B. At least 500 cells
were evaluated in each experiment and the error bars indicate
the S.D. from three independent experiments.
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observed in parental PC3 cells (Figs. 1B, c and 4A).
However, there was an increase (15^30%) in cells
containing one or two copies of centrosomes in
PC3-p53 cell lines, while there was a signi¢cant re-
duction of cells containing more than three copies of
centrosomes (up to 40%) (Fig. 4B^D). The majority
of the centrosomes in the p53-expressing PC3 cells
seemed to be similar in size, although enlarged cen-
trosomes could be observed occasionally. These ob-
servations indicate that introduction of p53 into PC3
cells not only a¡ected the growth properties, but also
signi¢cantly reduced centrosome ampli¢cation in
PC3 cells.
4. Discussion
Inactivation of p53 has been associated with cen-
trosome ampli¢cation and chromosome instability
(CIN) in many types of human cancers
[4,9,11,16,25]. In this study, we provided ¢rst evi-
dence on the e¡ect of p53 on centrosome ampli¢ca-
tion in human prostate cancer cells. Using three
prostate cancer cell lines containing di¡erent p53 sta-
tus, we found that loss of p53 function in DU145
and PC3 cells correlated to the increased centrosome
numbers and irregularity in structure, when com-
pared to the LNCap cells which expressed wild-
type p53 (P6 0.05, Figs. 1B and 2). Upon introduc-
tion of p53, we observed a G2/M arrest and a de-
crease in centrosome abnormality in PC3 cells (Figs.
3 and 4). Our results indicate that p53 may be in-
volved in the regulation of G2/M arrest in these pros-
tate cancer cells.
Our results agree with previous ¢ndings that ab-
normally ampli¢ed multiple copies of centrosomes
were observed in p533/3 mouse embryonic ¢bro-
blasts (MEF)[9]. In addition, loss of p53 function,
either by inactivation or gain of function mutation,
has been reported to result in an increased abnormal-
ity and hyperampli¢cation of centrosomes, as well as
chromosome instability [4,11,16]. Although we did
not perform cytogenetic studies on these cell lines,
a detailed chromosomal analysis using spectral kar-
yotyping (SKY) analysis have recently been reported
on LNCap, DU145 and PC3 cell lines [26]. It was
found that numerical abnormalities frequently de-
tected in LNCap cells were much less (involving
four chromosomes) than that in PC3 (involving 13
chromosomes) and DU145 (involving ten chromo-
somes) cell lines, while most frequent numerical ab-
normalities detected in all three cell lines were on two
chromosomes (chromosome 13 and 22). Our ¢ndings
in combination with previous evidence [26] suggest
that loss of p53 function may be associated with
increased chromosomal instability and centrosome
abnormalities in these cell lines.
p53 was initially thought to be involved in the
G1/S checkpoint control. However, increased evi-
dence suggests that p53 also functions at the G2/M
checkpoint. It has been reported that p533/3 MEF
cells are characterized by their high degree of aneu-
ploidy [27,28]. A strong correlation between inacti-
vation of p53 and aneuploidy has also been demon-
strated in number of studies [14,27,29]. In a human
ovarian cancer cell line, introduction of wild-type
p53 leads to arrest in G2/M phase but not in G1
[30]. In this study, we also found that introduction
of wild-type p53 into prostate cancer cell line PC3 led
to a G2/M delay (Fig. 3C). There was also a decrease
in the percentage of S-phase cells as determined by
BrdU incorporation and £ow cytometric analysis
(Fig. 3B,C), and a reduced cell growth rate (data
not shown). These suggest that expression of wild-
type p53 inhibits cell growth through G2/M arrest in
PC3 cells. In addition, it is recognized that most of
the human cancers are aneuploidy and the ploidy
changes become more extensive at later stage of the
tumor progression, when inactivation of p53 is com-
mon, indicating a strong relationship between loss of
p53 and chromosomal instability.
In the absence of p53, loss of checkpoint control in
the presence of mitotic defects will result in aneu-
ploidy. Loss of p53 in human and mouse cells leads
to centrosome ampli¢cation accompanying by in-
creased chromosomal abnormalities [4,9,16,25]. In
this study, we observed a decrease in centrosome
abnormalities after introduction of p53 into PC3 cells
(Fig. 4). After transfection, there was a signi¢cant
increase in cells containing one copy of centrosome
while a reduction in the number of cells containing
more than three copies (up to 40%, P6 0.05) (Fig.
4). This suggests that expression of wild-type p53
signi¢cantly decreases centrosome ampli¢cation in
PC3 cells. Although the exact mechanism as how
p53 is involved in centrosome regulation is not clear,
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evidence from MEF cells suggests that a centrosome
can undergo multiple cycles of duplication in a single
cell cycle in cells lacking of p53 [13]. In addition,
these abnormally ampli¢ed centrosomes can establish
pseudodiploidy which leads to chromosome mis-
segregation and gain or loss of chromosomes in the
daughter cells. A recent study indicates that p21waf1,
one of the downstream e¡ectors of p53, may be in-
volved in the regulation of p53-mediated centrosome
duplication [31]. We are currently investigating chro-
mosomal changes in these three PC3-p53 clones to
further study the relationship between p53 expression
and chromosomal instability in prostate cancer cells.
In summary, we have provided the ¢rst evidence
associating inactivation of p53 and increased centro-
some abnormalities in prostate cancer cells. The evi-
dence that introduction of p53 into PC3 cells results
in a G2/M delay and centrosome abnormality sug-
gests that p53 may play an important role in the
regulation of mitotic checkpoint control in these
cells. As CIN and p53 abnormality are commonly
found in prostate cancers, our evidence provides a
possible mechanism involved in chromosomal insta-
bility in prostate cancer.
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